Fulcin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fulcin

Quick Facts

Property Description
Active ingredient Griseofulvin
Form Tablets, capsules, oral suspension
Pharmacological class Systemic Antifungal Agent
Common purpose Halts the growth of fungal infections (dermatophytes)
Origin Synthetic (derived from Penicillium species)

What Type of Medicine is Fulcin (Griseofulvin)?

Fulcin is a foundational prescription-only medicine containing the active substance Griseofulvin, which is officially classified as a systemic antifungal agent or antimycotic drug. This classification places it in a specialized group of pharmaceuticals designed to combat pathogenic fungi. This medicine is clinically recognized for its long history of efficacy against susceptible fungal species. Unlike topical preparations, which are applied directly to the skin surface, Fulcin is a systemic medicine intended for oral administration, meaning it is absorbed internally and distributed throughout the body via the bloodstream. This systemic approach is essential for targeting infections deeply embedded within keratinized tissues, such as the hair, nails, and deeper layers of the skin, where external treatments cannot reach effectively.

Composition and Available Forms of Fulcin

The active compound, Griseofulvin, is a single-ingredient product, a synthetic substance originally derived from certain species of Penicillium. Fulcin is supplied in various dosage forms, including tablets, capsules, and an oral suspension. A differentiating factor in its formulation is the structural variation of the active substance into both microsize and ultramicrosize crystals. Griseofulvin acts by targeting structures involved in fungal cell division, defining its functional identity. This ultramicrosize preparation is specifically engineered for enhanced absorption from the gastrointestinal tract, ensuring better bioavailability.

General Purpose and Action of this Fungistatic Agent

The general purpose of Fulcin is to halt the growth and expansion of infections caused by dermatophytes, which are the specific fungi responsible for common conditions like athlete’s foot or ringworm (tinea). This medicine is characterized as a fungistatic agent, meaning its functional action is primarily centered on inhibiting the ability of the fungal pathogen to reproduce and multiply. By disrupting the growth process of the fungus, Fulcin allows the natural physiological process of tissue renewal to gradually replace the infected keratin structures with new, uninfected material, completing its therapeutic objective.

What side effects are possible with Fulcin?

Possible Side Effects and Safety Information

Griseofulvin, the active ingredient in Fulcin, has an officially documented safety profile categorized by frequency and affected organ system, based on regulatory labeling. Adverse reactions are grouped by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards.

Commonly reported effects include headache, which is often noted to be more frequent at the beginning of therapy but typically resolves spontaneously with continued use. Other common reactions are nausea, vomiting, diarrhea, and epigastric distress (gastrointestinal disorders), as well as dizziness and skin rashes.


Safety Considerations by System and Risk

Adverse effects are also classified by the System-Organ Class (SOC):

System-Organ Class Examples of Documented Effects
Nervous System Headache, dizziness, mental confusion, insomnia
Dermatological Rashes, urticaria, photosensitivity (caution with sun exposure)
Hepatobiliary Elevated liver enzymes, rare reports of liver toxicity

Serious Adverse Reactions are rare but officially documented, including severe cutaneous reactions (such as Stevens-Johnson syndrome) and blood dyscrasias like leukopenia (reduction in white blood cells). The official label notes a need for monitoring of renal, hepatic, and hematopoietic functions during long-term treatment.


Restrictions and Special Population Safety

Fulcin is contraindicated in patients with porphyria and severe hepatocellular failure (severe liver disease). It is also contraindicated during pregnancy due to the potential for fetal harm. Safety information further notes that Griseofulvin may reduce the efficacy of oral contraceptives, requiring additional barrier methods, and can potentiate the effects of alcohol.

Overdose and Emergency Response

The official regulatory profile for Fulcin (Griseofulvin) focuses primarily on mandating immediate emergency intervention due to the risk of severe complications rather than listing a unique set of mild overdose symptoms. Documented clinical presentations of overdose are not well established but may manifest as an exacerbation of common effects, including nausea, vomiting, headache, confusion, and numbness.

Regulators emphasize the potential for life-threatening outcomes such as Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and Hepatotoxicity (severe liver damage or jaundice), which are outcomes associated with potential hospitalization or death.

Immediate Medical Action Required

Immediate medical attention must be sought in the event of suspected overdose. The government-mandated instructions require that you call emergency services at once if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. This drug is managed with symptomatic and supportive treatment in a medical setting, as no specific antidote is known. Management procedures officially documented for drug elimination include gastric lavage and activated charcoal administration. Continuous monitoring of hepatic (liver), renal (kidney), and haematopoietic (blood) parameters is required as part of the management protocol.

Therapeutic Uses of Fulcin

Fulcin (Griseofulvin) is a systemic antifungal that is commonly used to help with dermatophyte infections of the skin, hair, and nails. It is considered relevant in clinical settings for Tinea capitis, Onychomycosis, and other Tinea infections that require comprehensive internal management.


Systemic Support for Deep and Refractory Symptoms

This medication is used across therapeutic contexts for managing infections where topical management may be insufficient, particularly when the fungal elements are deeply embedded within the nail beds or hair shafts. It is typically applied in addressing conditions presenting with disruptive symptom manifestations like nail discoloration and brittleness, patchy hair loss, and widespread, chronic skin lesions. Specifically, it is relevant for easing the symptom burden associated with Tinea capitis, Onychomycosis (fungal nail infection), Tinea corporis (ringworm of the body), and Tinea pedis (athlete's foot).


Quick Fact: Relief for Widespread Itching and Scaling This medication is commonly used to help with widespread skin fungal symptoms, assisting with the management of pervasive pruritus (itching) and chronic flaking associated with the infection.

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

Regulatory authorities define the specific populations permitted, restricted, or prohibited from using Fulcin (Griseofulvin). Use is generally allowed for adults and pediatric patients over 2 years of age. Safety and effectiveness have not been established for children 2 years old and younger.

Category Regulatory Status (Population must NOT use)
Absolute Contraindications History of hypersensitivity to griseofulvin, Porphyria, Severe Hepatic Impairment (Severe Liver Disease), or Systemic Lupus Erythematosus (SLE).
Reproductive Status Pregnant women and breastfeeding women.

Eligibility is conditional for certain groups. Patients with minor to moderate hepatic impairment must undergo regular monitoring of liver function during use. Furthermore, women of childbearing potential must use effective non-hormonal contraception throughout treatment and for 4 weeks post-therapy. Sexually active males must use barrier contraception during therapy and for 6 months after cessation, as stipulated in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Griseofulvin, the active ingredient in Fulcin, is formally documented as a hepatic microsomal enzyme inducer in regulatory labels, which is the basis for several clinically significant pharmacokinetic interactions. This enzyme induction may accelerate the metabolism and thus reduce the plasma levels and efficacy of certain co-administered medicinal products.

Documented Interaction Patterns

Interacting Substance/Class Official Interaction Description
Oral Contraceptives (Estrogen-containing) Reduced efficacy and potential for breakthrough bleeding, requiring the use of additional barrier contraception during and after therapy.
Warfarin-type Anticoagulants Decreased anticoagulant activity, which necessitates careful management of the anticoagulant dosage.
Barbiturates (e.g., Phenobarbital) May reduce the bioavailability and blood plasma levels of Griseofulvin, potentially depressing its activity.
Ciclosporin May result in the documented reduction of ciclosporin plasma levels, requiring monitoring.

Restrictions and Administration Constraints

Co-administration with alcohol is formally restricted due to the documented risk of a disulfiram-like reaction (flushing, nausea) and the enhancement of Central Nervous System (CNS) effects. Regulatory information also advises that the medicine must be taken with food, specifically a high-fat meal, to ensure optimal absorption and achieve the intended plasma concentration. Additionally, products like antacids and H2 antagonists may impair absorption and should be separated by a time interval following administration.

Mechanism of Action

Interference with Fungal Cell Division (Mitotic Arrest)

The core mechanism involves the drug acting as a fungistatic inhibitor by binding specifically to tubulin within the fungal cell. This molecular interaction physically disrupts the formation of the mitotic spindle, a structure essential for separating chromosomes during cell division. By arresting the fungal cell cycle at the metaphase stage, the drug prevents the pathogen from multiplying, which is the necessary physiological precursor to the subsequent replacement of infected tissue.

Physical Resistance in New Keratin Structures

The drug’s final physiological consequence depends on its unique second domain: systemic incorporation into new keratin. Griseofulvin is deposited in keratin precursor cells and binds to the forming keratin protein in the hair, nails, and outer skin layers. This creates a fungus-resistant barrier that renders the newly growing tissue resistant to colonization. The resulting physiological effect—the complete replacement of infected tissue—is therefore directly coupled to the natural, slow growth rate of the host's keratinized structures.

Dosage and Administration Information

Fulcin, which contains the active substance Griseofulvin, is administered solely by the oral route, functioning as a systemic antifungal agent. The overall usage protocol is defined by the specific dosage form and the mandatory conditions required for optimal absorption. The active ingredient is available in both microsize and ultramicrosize crystal formulations, with the latter designed for enhanced systemic uptake.

For adults, daily doses of the microsize formulation generally range from 500 mg for certain skin infections up to 1000 mg (1 g) for difficult-to-treat infections like those affecting the nails and feet. The corresponding ultramicrosize dose is typically 375 mg or 750 mg daily. The medicine is usually taken once daily or in divided doses.

A critical instruction is to take Fulcin with or immediately after a high-fat meal or milk to significantly increase the amount of medicine absorbed into the body. Treatment duration is prolonged and is determined by the rate at which the infected tissues are replaced by new, healthy growth. For example, skin infections may require treatment for 2 to 4 weeks, while infections of the toenails may necessitate continuous administration for six months to over a year. Pediatric dosing for children over the age of two is calculated based on body weight, but a formal dosage has not been established for children under two years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fulcin (Griseofulvin)

The research surrounding Fulcin (Griseofulvin) describes the research scope, which includes studies examining its use in research contexts involving systemic management of fungal infections that involve keratinized tissues like the hair, nails, and skin. Studies have been conducted over several decades, utilizing established clinical trial methods to examine measured outcomes.

Evidence for Use in Tinea Capitis (Scalp Infection)

Research examining the use of Fulcin for ringworm of the scalp, known as Tinea capitis, has primarily utilized Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that consolidate findings from multiple trials. Research examined these outcomes, mainly in the pediatric population. Researchers were keen to measure two specific outcomes: Mycological Cure (clearance of the fungus itself, confirmed by laboratory testing) and Clinical Cure (resolution of visible signs like scaling and hair loss). Studies monitored how outcomes evolved in the observed populations during the defined treatment intervals, with findings describing patterns observed in the time required to meet the definition of fungal clearance used in the study.

Evidence for Use in Onychomycosis (Fungal Nail Infection)

For fungal nail infections (Onychomycosis), studies have utilized RCTs and systematic reviews to explore the evidence landscape. Since nails grow slowly, this research was applied in studies examining patient-reported experiences and monitoring outcomes related to systemic or functional imbalance over long follow-up durations, often extending beyond six months to over a year. The trials were designed to measure both the clearance of the fungus and the subsequent return of the nail to a normal appearance. Findings describe patterns observed in the measured outcomes related to mycological and clinical changes.

What is Still Uncertain About Fulcin Research

Research indicates that follow-up durations were limited across the evidence landscape for fully establishing long-term outcomes and recurrence patterns. Comparative evidence is lacking for specific, detailed comparisons of modern formulations or for treatment lengths for generalized skin infections. Findings were mixed in some comparative studies, and evidence quality varies across studies, particularly among older historical trials. The research provides context but not individual predictions, and findings help contextualize what is known—and what is still uncertain—about this medicine's measured outcomes.

Key Studies & References

  1. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis
  2. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis
  3. Oral treatments for toenail onychomycosis: a systematic review
  4. Label: GRISEOFULVIN tablet - DailyMed (FDA Label)

Frequently Asked Questions (FAQ)

Common questions about Fulcin (FAQ)

Q: Is Fulcin considered a type of antibiotic?

Official classifications state that Griseofulvin, the active substance in Fulcin, is an antifungal antibiotic. The drug is effective against the specific fungal organisms known as dermatophytes. This classification places it in a specialized group of medicines used to combat pathogenic fungi.

Q: Does Fulcin work the same way as common topical antifungal creams?

No. Fulcin is a systemic medicine taken orally, designed to work from the inside, via the bloodstream. Regulatory information notes that the medication is generally not effective when applied topically (to the skin surface), which is why it is used for deeper infections.

Q: How quickly does Fulcin typically start to show its effects?

The medication begins working immediately at the cellular level by halting fungal cell division. However, visible improvement may take a few days or even weeks. This is because the drug’s effectiveness depends on the natural, slow growth rate of new, uninfected skin, hair, or nails to replace the infected tissue.

Q: What are the signs of a serious allergic reaction to Fulcin described in official documents?

Regulatory documents describe signs of a severe allergic reaction which can include skin changes like hives, blistering, or peeling, as well as fever. Other serious signs may involve swelling of the face or tongue. If these symptoms occur, it is essential to seek prompt medical attention.

Q: Do side effects from Fulcin usually go away after the first few weeks?

Official information indicates that some common, mild side effects may resolve or lessen spontaneously with continued use as the body adjusts to the medication. For example, a headache is often noted to disappear during continued therapy. It is important to note, however, that this does not apply to all adverse effects.

Q: Are there any common foods or drinks to avoid while taking Fulcin?

The consumption of alcohol is formally restricted while taking Fulcin. Regulatory warnings state that alcohol may enhance the effects of the medication or lead to a disulfiram-like reaction, which causes uncomfortable symptoms like flushing and a fast heartbeat.

Q: Is Fulcin usage restricted by having a specific food or drug allergy?

The drug is contraindicated for anyone with a known hypersensitivity (allergy) to griseofulvin itself. The active substance is derived from a species of Penicillium mold, and official information advises caution for individuals with known penicillin allergies.

Q: Are there any specific organ conditions (like kidney issues) that prevent someone from using Fulcin?

Fulcin is contraindicated in patients who have porphyria or severe hepatic impairment (severe liver disease). While regulatory information recommends periodic monitoring of renal (kidney) function, renal insufficiency is not listed as a contraindication for use.

Q: Does Fulcin treat yeast infections in general?

No, official regulatory documents state that Griseofulvin is not effective against yeast (such as Candida) or other non-dermatophyte fungi. The medicine is primarily used for infections caused by dermatophytes. In rare instances, patients taking Fulcin have reported a yeast infection (oral thrush) as a side effect.

Q: What research exists on the long-term effects of taking Fulcin?

Since treatment is often prolonged, regulatory documents address potential long-term risks. Serious adverse effects, such as liver issues or neurological symptoms, are sometimes associated with high dosages or prolonged therapy. For this reason, periodic monitoring of organ function is recommended.

Q: Is Fulcin a generic medication or still only available under brand names?

The active substance, Griseofulvin, is available as a generic medication. Additionally, different pharmaceutical companies market the drug under various brand names, which may include Fulvicin, Gris-Peg, or Grisovin, depending on the region.

Q: What restrictions are there on driving or operating machinery while using Fulcin?

Official prescribing information advises avoiding driving or operating machinery until the patient understands how the medicine affects their ability to perform skilled tasks. This is because the medication may cause dizziness and mental confusion.

Q: Can older adults (seniors) safely take Fulcin?

No specific contraindication is listed in official documents based solely on age, meaning use in seniors is permitted. However, regulatory bodies recommend periodic monitoring of essential organ functions (liver, kidney, blood) during prolonged use in all adult patients, including older adults.

Q: How long does Fulcin stay in the body after the last dose?

The elimination half-life of Griseofulvin—the time required for the amount of medicine in the bloodstream to be reduced by half—is variable. Regulatory pharmacokinetic data indicates this duration typically ranges from 9 to 24 hours.

Q: What should be done if a dose of Fulcin is missed?

Regulatory patient leaflets typically contain specific guidance for managing a missed dose. These instructions commonly advise that if a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. For precise and individualized instruction, referring to the patient information leaflet or consulting a healthcare professional is advised.

Q: Does Fulcin need to be taken at the exact same time every day?

Regulatory patient information generally recommends taking the medication at about the same time each day. This practice helps maintain consistent blood levels of the medicine, which is necessary for effective treatment, and aids in adhering to the schedule.

Q: What if the treated condition seems to be getting worse after starting Fulcin?

If the treated condition appears to be worsening or is not showing any improvement, official advice suggests contacting a healthcare provider for further evaluation. Patients are advised to continue taking the medication as prescribed unless directed otherwise by a healthcare professional.

Q: Why is Fulcin sometimes used when other antifungal treatments haven't worked?

Official information states that the medication is often reserved for use when topical treatments, such as creams, have failed to clear the infection. This is because Fulcin is a systemic medicine designed to target infections that are deep within keratinized tissues (hair, nails) where external agents cannot penetrate effectively.

Q: Why do I sometimes see Fulcin referred to by a different brand name?

The name Fulcin is a specific brand name. Because Griseofulvin is the generic active substance, different pharmaceutical companies market the drug under various regional brand names, which may include names such as Gris-Peg, Grisovin, or Fulvicin.

Q: Does Fulcin contain penicillin or sulfa ingredients?

The active substance, Griseofulvin, is derived from a species of Penicillium mold. Although it originates from this mold, it is not considered a penicillin-type antibiotic. Regulatory information does not indicate that the drug contains sulfa ingredients.

Q: Is there any evidence that Fulcin is becoming less effective over time (drug resistance)?

Regulatory documents mention that there have been reports of dermatophyte resistance to griseofulvin in laboratory studies. However, official information clarifies that the clinical significance of these reports—meaning how they affect real-world treatment—has not been established.

How should Fulcin be stored and disposed of?

How to Store and Dispose of Fulcin (Griseofulvin)

Official regulatory labeling dictates specific conditions for the storage and disposal of Fulcin to maintain product stability and safety.

Regulatory Storage Requirements

Griseofulvin tablets must be stored at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F). The product must be protected from heat, moisture, and direct light, and it is explicitly stated to keep from freezing. The container must be kept tightly closed and stored out of the reach of children.

Official Disposal Instructions

Expired or unused Fulcin should be disposed of properly. The preferred method is utilizing community drug take-back programs. If this is not possible, the medicine can be thrown into household trash after being mixed with an undesirable substance, such as coffee grounds or cat litter, and sealed. Fulcin is not recommended for flushing down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fulcin found in:

A-Z Index: